Lv51
1380 积分 2023-11-02 加入
Using forest plots to interpret covariate effects in pharmacometric models
18天前
已完结
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
1个月前
已完结
Pharmacokinetic models for first-in-human dose selection of immune-activating products in oncology
1个月前
已完结
Model-Based Meta-Analysis of IL-17 A Inhibitors for Moderate-to-Severe Plaque Psoriasis: Establishing Exposure-Response Relationships to Inform Targeted Drug Development
1个月前
已完结
Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer
1个月前
已完结
1446P Preliminary efficacy and safety of rilvegostomig (AZD2936), a bispecific antibody targeting PD-1 and TIGIT, in checkpoint inhibitor (CPI)-pretreated advanced/metastatic non-small-cell lung cancer (NSCLC): ARTEMIDE-01
2个月前
已完结
Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial
3个月前
已完结
IMpower150 Final Exploratory Analyses for Atezolizumab Plus Bevacizumab and Chemotherapy in Key NSCLC Patient Subgroups With EGFR Mutations or Metastases in the Liver or Brain
3个月前
已完结
50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic
3个月前
已完结
Subgroup analyses in clinical research: too tempting?
4个月前
已完结
皖公网安备34019202002308
